The Future Is Now in Community-Acquired Pneumonia: Cardiovascular Complications and Conjugate Vaccines;Neumonía adquirida en la comunidad, el futuro en el presente: Complicaciones cardiovasculares y vacunas conjugadas

Archivos de Bronconeumologia

Volumn 48, Issue 10, 2012, Pages 347-348

  Aspa, Javier ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

CARDIOVASCULAR DISEASE; COMMUNITY ACQUIRED PNEUMONIA; EDITORIAL;

EID: 84866514114     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2012.07.008     Document Type: Article

References (26)

1. Woodhead M., Blasi F., Ewig S., Garau J., Huchon G., Ieven M., et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clin Microbiol Infect 2011, 17(Suppl. 6):E1L 59.
2. Menendez R., Torres A., Aspa J., Capelastegui A., Prat C., Rodriguez de Castro F. Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR). Arch Bronconeumol 2011, 46:543-558.
3. Waterer G.W., Rello J., Wunderink R.G. Management of community-acquired pneumonia in adults. Am J Respir Crit Care Med 2011, 183:157-164.
4. Bordon J., Wiemken T., Peyrani P., Paz M.L., Gnoni M., Cabral P., et al. Decrease in long-term survival for hospitalized patients with community-acquired pneumonia. Chest 2010, 138:279-283.
5. Waterer G.W., Kessler L.A., Wunderink R.G. Medium-term survival after hospitalization with community-acquired pneumonia. Am J Respir Crit Care Med 2004, 169:910-914.
6. Johnstone J., Eurich D.T., Majumdar S.R., Jin Y., Marrie T.J. Long-term morbidity and mortality after hospitalization with community-acquired pneumonia: a population-based cohort study. Medicine (Baltimore) 2008, 87:329-334.
7. Corrales-Medina V.F., Suh K.N., Rose G., Chirinos J.A., Doucette S., Cameron D.W., et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med 2011, 8:e1001048.
8. Perry T.W., Pugh M.J., Waterer G.W., Nakashima B., Orihuela C.J., Copeland L.A., et al. Incidence of cardiovascular events after hospital admission for pneumonia. Am J Med 2011, 124:244-251.
9. Jasti H., Mortensen E.M., Obrosky D.S., Kapoor W.N., Fine M.J. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2008, 46:550-556.
10. Corrales-Medina V.F., Serpa J., Rueda A.M., Giordano T.P., Bozkurt B., Madjid M., et al. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore) 2009, 88:154-159.
11. Milbrandt E.B., Reade M.C., Lee M., Shook S.L., Angus D.C., Kong L., et al. Prevalence and significance of coagulation abnormalities in community-acquired pneumonia. Mol Med 2009, 15:438-445.
12. Martinez R., Menendez R., Reyes S., Polverino E., Cilloniz C., Martinez A., et al. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J 2011, 37:393-399.
13. Yende S., D'Angelo G., Kellum J.A., Weissfeld L., Fine J., Welch R.D., et al. Inflammatory markers at hospital discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med 2008, 177:1242-1247.
14. Kruger S., Ewig S., Giersdorf S., Hartmann O., Suttorp N., Welte T. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 2010, 182:1426-1434.
15. Bello S., Lasierra A.B., Minchole E., Fandos S., Ruiz M.A., Vera E., et al. Prognostic power of proadrenomedullin in community-acquired pneumonia is independent of etiology. Eur Respir J 2011 Nov 10, [Epub ahead of print] PMID: 22075489.
16. Jackson L.A., Neuzil K.M., Yu O., Benson P., Barlow W.E., Adams A.L., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003, 348:1747-1755.
17. Huss A., Scott P., Stuck A.E., Trotter C., Egger M. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180:48-58.
18. Johnstone J., Eurich D.T., Minhas J.K., Marrie T.J., Majumdar S.R. Impact of the pneumococcal vaccine on long-term morbidity and mortality of adults at high risk for pneumonia. Clin Infect Dis 2010, 51:15-22.
19. Weycker D., Strutton D., Edelsberg J., Sato R., Jackson L.A. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine 2010, 28:4955-4960.
20. Gil-Prieto R., Garcia-Garcia L., Alvaro-Meca A., Mendez C., Garcia A., De Miguel A.G. The burden of hospitalisations for community-acquired pneumonia (CAP) and pneumococcal pneumonia in adults in Spain (2003-2007). Vaccine 2011, 29:412-416.
21. Picazo J., Ruiz-Contreras J., Casado-Flores J., Giangaspro E., Del Castillo F., Hernandez-Sampelayo T., et al. Relationship between serotypes, age, and clinical presentation of invasive pneumococcal disease in Madrid, Spain, after introduction of the 7-valent pneumococcal conjugate vaccine into the vaccination calendar. Clin Vaccine Immunol 2011, 18:89-94.
22. Miller E., Andrews N.J., Waight P.A., Slack M.P., George R.C. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis 2011, 11:760-768.
23. French N., Gordon S.B., Mwalukomo T., White S.A., Mwafulirwa G., Longwe H., et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med 2010, 362:812-822.
24. Hicks L.A., Harrison L.H., Flannery B., Hadler J.L., Schaffner W., Craig A.S., et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis 2007, 196:1346-1354.
25. Pilishvili T., Lexau C., Farley M.M., Hadler J., Harrison L.H., Bennett N.M., et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010, 201:32-41.
26. Smith K.J., Wateska A.R., Nowalk M.P., Raymund M., Nuorti J.P., Zimmerman R.K. Cost-effectiveness of adult vaccination strategies using pneumococcal conjugate vaccine compared with pneumococcal polysaccharide vaccine. JAMA 2012, 307:804-812.